Incyte (INCY) Growth Rates Comparisons to Medical Laboratories Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Customers, else..
 
Incyte Corporation  (NASDAQ: INCY)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

Incyte Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

INCY Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q1 MRQ) 20.87 % 9.3 % 8.91 % 10.9 %
Q / Q Revenue Growth (Q1 MRQ) -15.54 % -4.17 % -3.28 % 8.32 %
Y / Y Revenue Growth (for 12 months ending Q1 TTM) 21.48 % 9.49 % 7.98 % %
Sequential Revenue Growth (for 12 months ending Q1 TTM) 4.27 % 2.32 % 2.03 % 2.61 %
Revenue 5 Year Average Growth 14.03 % 13.12 % 8.65 % 10.59 %


INCY's Growth Comparisons in I. Quarter 2026




Strong but slowing Revenue rise by Incyte of 20.87% year on year , in the first quarter 2026 to 1.27 billions, was higher than the 9.3% growth in the Medical Laboratories industry, and 8.91% growth in the Healthcare sector. Despite modest Sales rises in the Healthcare sector and in the Medical Laboratories industry, Incyte Corporation reported above average market Sales growth.

Comparing company's Revenue to the fourth quarter results, sales were lower by -15.54% . On the annual basis, average annual sales growth for Incyte is 14.03%, while S & P 500's including only Businesses with the first quarter 2026 results, average yearly sales growth is 10.59% over the past five years.

INCY Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Net sales
19.76 %
-
JAKAFI
6.81 %
-
OPZELURA
399.35 %
-
ICLUSIG
136.45 %
-
PEMAZYRE
149.25 %
-
MINJUVI MONJUVI
66.58 %
-
NIKTIMVO
747.7 %
-
ZYNYZ
2935.56 %
-
Product royalty revenues
15.75 %
-
JAKAVI Royalty
14.55 %
-
OLUMIANT Royalty
17.21 %
-
TABRECTA Royalty
-6.72 %
-
Other product royalty revenues
577.49 %
-
Milestone and contract revenues
-
-
Reportable Segment
20.87 %
-
Net sales Reportable Segment
19.76 %
-
Product royalty revenues Reportable Segment
15.75 %
-
Milestone and contract revenues Reportable Segment
-
-
United States
-
-
Europe
187.94 %
-
Other countries
-
-
Total
20.87 %
-75.25 %
Product
-
-
Royalty
-
-
MINJUVI/MONJUVI
-
-
Jakavi Royalty Revenues
-
-
Olumiant Royalty Revenues
-
-
Tabrecta Royalty Revenues
-
-
Jakavi
-
-
Tabrecta
-
-
Olumiant
-
-
Reportable
-
-


Growth Rates of INCY's Income in the first quarter 2026


INCY Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q1 MRQ) 46.77 % 51.98 % 4.62 % 97.6 %
Sequential Operating Income Change (Q1 MRQ) -10.34 % 0.29 % 0.89 % 48.13 %
Y / Y Operating Income Growth (Q1 TTM) 822.38 % 91.48 % 30.73 % 40.67 %
Sequential Operating Income Growth (Q1 TTM) 6.33 % 10.42 % 4.82 % 20.86 %
Operating Income 5 Year Avg. Change - 6.34 % 10.39 % 18.76 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q1 MRQ) 91.73 % 29.87 % -25.98 % 90.69 %
Sequential Income from Cont. Ops. Change (Q1 MRQ) 1.35 % 7.6 % -66.16 % 27.07 %
Y / Y Income from Cont. Ops. Change (Q1 TTM) 6631.44 % 3.68 % 2.68 % 57.33 %
Sequential Income from Cont. Ops. Change (Q1 TTM) 11.28 % 14.82 % -5.02 % 18.65 %
Income from Cont. Ops. 5 Year Avg. Change - 5.07 % 0.17 % -28.52 %

INCY Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q1 MRQ) 91.73 % 10.96 % -26.26 % 90.69 %
Q / Q Net Income Growth (Q1 MRQ) 1.35 % 6.76 % -0.77 % 27.07 %
Y / Y Net Income Change (Q1 TTM) 6631.44 % 186.84 % 15.51 % 57.33 %
Sequential Net Income Change (Q1 TTM) 11.28 % 13.58 % -6.72 % 18.65 %
Net Income 5 Year Avg. Growth - 5.34 % 9.21 % 22.96 %

INCY's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q1 MRQ) 85.37 % 21.52 % -25.98 % 90.69 %
Sequential EPS from Cont. Ops. Change (Q1 MRQ) -0.65 % 1.6 % -66.16 % 27.07 %
Y / Y EPS from Cont. Ops. Change (Q1 TTM) 2336.67 % - - -
Sequential EPS from Cont. Ops. Change (Q1 TTM) 10.59 % - - 4.88 %
EPS from Cont. Ops. 5 Year Avg. Growth - -8.23 % 0.17 % -28.52 %



INCY EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q1 MRQ) 83.75 % 3.82 % -26.26 % -28.52 %
Q / Q EPS Net Growth (Q1 MRQ) -1.34 % 0.81 % -0.77 % 27.07 %
Y / Y EPS Net Change (for 12 months ending Q1 TTM) - - - 7.62 %
Sequential EPS Net Change (for 12 months ending Q1 TTM) 10.4 % - - 4.93 %
EPS Net 5 Year Avg. Change - 5.34 % 9.21 % 22.96 %



Incyte showed respectable 83.75% year on year rise of EPS in the first quarter, comparing favorably to the 3.82% growth in the Medical Laboratories industry, and -26.26% cut in the Healthcare sector.

the bottom-line fell by -1.34% from the fourth quarter. Average annual income per share growth for Incyte is 14.03%, while S & P 500's average yearly income per share increase is 22.96%, including only Businesses with the first quarter 2026 earnings.

INCY Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q1 MRQ) 34.71 % -2.81 % 48.49 % 48.62 %
Sequential Free Cash Flow Change (Q1 MRQ) -32.08 % -74.49 % -46.96 % 34.18 %
Y / Y Free Cash Flow Change (Q1 TTM) 391.98 % 28.27 % 18.61 % 60.27 %
Sequential Free Cash Flow Change (Q1 TTM) 6.86 % 0.68 % 5.39 % 15.75 %
Free Cash Flow 5 Year Avg. Change - 10.39 % 0.92 % 8.28 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q1 MRQ) 43.06 % - - 339.02 %
Sequential Net Cash Flow Change (Q1 MRQ) -43.49 % - - 216.68 %
Y / Y Net Cash Flow Change (Q1 TTM) - - - 209.43 %
Sequential Net Cash Flow Change (Q1 TTM) - 16.28 % - 152.64 %
Net Cash Flow 5 Year Avg. Change - -9.51 % 6.46 % 1.06 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q1 MRQ) 379.65 % 46.14 % 8.23 % 120.03 %
Sequential Capital Expenditures Change (Q1 MRQ) -30.52 % -1.79 % -22.09 % 36.87 %
Y / Y Capital Expenditures Change (Q1 TTM) 2.26 % 23.91 % 7.87 % 109.38 %
Sequential Capital Expenditures Change (Q1 TTM) 14.35 % 11.21 % 1.6 % 23.05 %
Capital Expenditures 5 Year Avg. Change -14.85 % 8.7 % 9.18 % 14.72 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.